Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: an EPS miss, increased cash burn, and reduced cash reserves, suggesting financial instability. Regulatory and competitive risks further exacerbate uncertainties. Despite some optimism in product development, unclear management responses in the Q&A and the lack of guidance add to the negative sentiment. The net loss improvement is overshadowed by operational challenges and financial concerns, leading to a predicted stock movement of -2% to -8%.
Cash Balance $27.1 million, a decrease of $17.8 million from $44.9 million as of December 31, 2024, due to cash used in operations.
Cash Used in Operations $18.1 million, an increase of $5.1 million from $13 million for the same period in 2024, reflecting increased operational activities.
Research and Development Expense $12 million, a decrease of $1.3 million from $13.3 million for the first quarter of 2024, primarily driven by lower study costs from completed clinical trials for REL-1017, offset by payments for sepranolone acquisition and NDV-01 in-licensing.
General and Administrative Expense $6.3 million, a decrease of approximately $3.4 million from $9.7 million for the first quarter of 2024, primarily due to a decrease in stock-based compensation expense.
Net Loss $17.6 million, or $0.58 per share, an improvement from a net loss of $21.8 million, or $0.72 per share for the first quarter of 2024, indicating better cost management.
New Product Candidates: Relmada added two unique product candidates: NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both showing promising Phase 2 data.
NDV-01 Phase 2 Data: Positive proof-of-concept data for NDV-01 presented at AUA 2025, showing an overall response rate of 85% and high-grade recurrence-free survival of 83% in patients with papillary disease.
Sepranolone Acquisition: Relmada acquired sepranolone from Asarina Pharma, targeting compulsive behavior disorders with promising Phase 2 results.
Market Opportunity for NDV-01: NDV-01 targets the bladder cancer market, with approximately 75,000 new cases diagnosed annually in the U.S., half of which are high-grade with a high risk of recurrence.
Market Opportunity for Sepranolone: Sepranolone is aimed at treating Prader-Willi syndrome and Tourette syndrome, with an estimated 350,000 people affected worldwide.
Cash Position: Relmada reported a cash balance of $27.1 million as of March 31, 2025, down from $44.9 million at the end of 2024.
R&D Expense Reduction: Research and development expenses decreased to $12 million in Q1 2025 from $13.3 million in Q1 2024.
G&A Expense Reduction: General and administrative expenses decreased to $6.3 million in Q1 2025 from $9.7 million in Q1 2024.
Strategic Focus: Relmada is focused on advancing NDV-01 and sepranolone through key development milestones, with plans for further studies and FDA interactions.
Earnings Miss: Relmada Therapeutics reported an EPS of -$0.58, missing expectations of -$0.31, indicating potential financial instability.
Cash Burn Rate: The company reported cash used in operations of $18.1 million for Q1 2025, an increase from $13 million in Q1 2024, raising concerns about sustainability.
Cash Reserves: Relmada's cash balance decreased to $27.1 million from $44.9 million, which may limit operational flexibility and funding for ongoing projects.
Regulatory Risks: The company is preparing for FDA interactions and further development of product supply for sepranolone, which involves inherent regulatory uncertainties.
Market Competition: Relmada faces competitive pressures in the oncology and CNS markets, particularly with NDV-01 and sepranolone, which may affect market share and pricing.
Clinical Development Risks: The advancement of NDV-01 and sepranolone into clinical development is contingent on successful regulatory approvals and clinical trial outcomes, which are uncertain.
Operational Challenges: The need for special handling and preparation of conventional chemotherapy agents poses operational challenges for NDV-01's market entry.
Product Candidates: Relmada added two unique product candidates, NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both showing promising Phase 2 data.
Clinical Milestones: The company is preparing to begin the next set of studies for NDV-01 and sepranolone, aiming to bring these programs to patients as soon as possible.
Market Opportunity: NDV-01 targets a market with approximately 75,000 new bladder cancer cases annually in the U.S., with a significant portion being high-grade disease.
Financial Position: Relmada reported a cash balance of $27.1 million, indicating a clean balance sheet and a disciplined development plan.
Cash Utilization: Cash used in operations for Q1 2025 was $18.1 million, compared to $13 million for the same period in 2024.
R&D Expenses: Research and development expenses for Q1 2025 totaled $12 million, a decrease from $13.3 million in Q1 2024.
Net Loss: The net loss for Q1 2025 was $17.6 million, or $0.58 per share, an improvement from a net loss of $21.8 million, or $0.72 per share in Q1 2024.
Future Development: Plans to advance sepranolone into clinical development in early 2026, with ongoing efforts to secure U.S. IND clearance for NDV-01.
Cash Balance: $27.1 million cash balance as of March 31, 2025.
Cash Used in Operations: $18.1 million cash used in operations for Q1 2025.
Net Loss: Net loss of $17.6 million, or $0.58 per share for Q1 2025.
Comparison of Net Loss: Net loss was $21.8 million, or $0.72 per share for Q1 2024.
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
The earnings call reveals several concerns: an EPS miss, increased cash burn, and reduced cash reserves, suggesting financial instability. Regulatory and competitive risks further exacerbate uncertainties. Despite some optimism in product development, unclear management responses in the Q&A and the lack of guidance add to the negative sentiment. The net loss improvement is overshadowed by operational challenges and financial concerns, leading to a predicted stock movement of -2% to -8%.
The earnings call reveals financial challenges, including a shrinking cash balance and increased cash used in operations, raising liquidity concerns. Despite some positive indicators like reduced net loss and promising initial data for NDV-01, the lack of clear guidance and potential regulatory and operational risks overshadow the positives. The management's vague responses in the Q&A add to the uncertainty. Given these factors, a negative sentiment is warranted, suggesting a potential stock price decline of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
